CA2388517A1 - Compositions et methodes permettant de reguler l'expression des antigenes specifiques de tumeurs - Google Patents

Compositions et methodes permettant de reguler l'expression des antigenes specifiques de tumeurs Download PDF

Info

Publication number
CA2388517A1
CA2388517A1 CA002388517A CA2388517A CA2388517A1 CA 2388517 A1 CA2388517 A1 CA 2388517A1 CA 002388517 A CA002388517 A CA 002388517A CA 2388517 A CA2388517 A CA 2388517A CA 2388517 A1 CA2388517 A1 CA 2388517A1
Authority
CA
Canada
Prior art keywords
tumor
cells
antigen
agent
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002388517A
Other languages
English (en)
Inventor
James T. Kurnick
Paul J. Durda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2388517A1 publication Critical patent/CA2388517A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/46449Melanoma antigens
    • A61K39/464491Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)

Abstract

L'invention concerne des méthodes et des compositions destinées au traitement de tumeurs. L'invention concerne en particulier des méthodes et des agents destinés au traitement de tumeurs qui expriment un antigène tumoral [également appelé antigène spécifique de tumeurs (TAA), antigène spécifique de lignée, antigène de différentiation ou autoantigène] et plus particulièrement des méthodes et des agents destinés au traitement de mélanomes qui expriment l'antigène Melan-A/MART-1. L'invention concerne également des méthodes permettant d'identifier des agents qui régulent l'expression des antigènes tumoraux.
CA002388517A 1999-11-16 2000-11-15 Compositions et methodes permettant de reguler l'expression des antigenes specifiques de tumeurs Abandoned CA2388517A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16580699P 1999-11-16 1999-11-16
US60/165,806 1999-11-16
PCT/US2000/031511 WO2001036472A2 (fr) 1999-11-16 2000-11-15 Compositions et methodes permettant de reguler l'expression des antigenes specifiques de tumeurs

Publications (1)

Publication Number Publication Date
CA2388517A1 true CA2388517A1 (fr) 2001-05-25

Family

ID=22600560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002388517A Abandoned CA2388517A1 (fr) 1999-11-16 2000-11-15 Compositions et methodes permettant de reguler l'expression des antigenes specifiques de tumeurs

Country Status (5)

Country Link
EP (1) EP1232178A2 (fr)
JP (1) JP2003515535A (fr)
AU (3) AU1615701A (fr)
CA (1) CA2388517A1 (fr)
WO (3) WO2001036461A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
JP4693902B2 (ja) * 2005-06-23 2011-06-01 バイエル ヘルスケア エルエルシー 体液中のrasp21の定量的検定法
WO2009069668A1 (fr) * 2007-11-28 2009-06-04 National University Corporation Nagoya University Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation
BRPI0922344A2 (pt) 2008-12-19 2017-10-24 3B Pharmaceuticals Gmbh inibidores de tfpi e métodos de uso
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
JP2015514070A (ja) 2012-03-21 2015-05-18 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Tfpi阻害剤および使用方法
CA2906587C (fr) 2013-03-13 2023-02-14 Health Research, Inc. Compositions et procedes pour l'utilisation de recepteurs de lymphocytes t recombinants pour la reconnaissance directe d'un antigene tumoral
US9550828B2 (en) * 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
NZ237533A (en) * 1990-03-29 1992-12-23 Bristol Myers Squibb Co Monoclonal antibodies which bind to oncostatin m, cell lines producing them
ZA912137B (en) * 1990-03-29 1992-11-25 Oncogen Monocional antibodies that inhibit growth of kaposi's sarcoma
US6020478A (en) * 1997-02-28 2000-02-01 Incyte Pharmaceuticals, Inc. Human tumor-associated antigen

Also Published As

Publication number Publication date
AU2043201A (en) 2001-05-30
WO2001036472A2 (fr) 2001-05-25
JP2003515535A (ja) 2003-05-07
WO2001036461A3 (fr) 2002-01-17
AU1615701A (en) 2001-05-30
AU2236201A (en) 2001-05-30
WO2001035903A2 (fr) 2001-05-25
EP1232178A2 (fr) 2002-08-21
WO2001036461A2 (fr) 2001-05-25
WO2001036472A3 (fr) 2002-01-10

Similar Documents

Publication Publication Date Title
CN110545883B (zh) 针对cd19的人源化抗原结合结构域及其使用方法
EP3360899B1 (fr) Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcinoembryonnaire (ceacam)
US20210338733A1 (en) Tn-MUC1 Chimeric Antigen Receptor (CAR) T Cell Therapy
EP2192179B1 (fr) Peptide cdh3 et agent médicinal le comprenant
CN118878692A (zh) 双特异性抗体组合物及其使用方法
US20210268020A1 (en) Compositions and methods of enhancing anti-tumor response using hybrid neutrophils
RU2598719C2 (ru) Средства для лечения заболевания
US11697685B2 (en) Chimeric antigen receptor cells targeting ROBO1, preparation method and use thereof
March et al. Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule
Chen et al. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer
US11014974B2 (en) Non-antibody binding proteins binding to PD-1 receptors and uses thereof
CA2388517A1 (fr) Compositions et methodes permettant de reguler l'expression des antigenes specifiques de tumeurs
EP1712563A1 (fr) Methode pour isoler des monocytes
AU2021389909A1 (en) Ras mutant epitope peptide and t cell receptor recognizing ras mutant
AU2003222221A1 (en) Map-kinase inhibitors as regulators of tumour-associated antigen expression
CN117120091A (zh) 靶向pd-1和tim-3的双特异性抗体
Takheaw et al. Transcriptome Analysis Reveals the Induction of Apoptosis-Related Genes by a Monoclonal Antibody against a New Epitope of CD99 on T-Acute Lymphoblastic Leukemia
US20230057987A1 (en) Antigen binding proteins specifically binding ct45
Devreux Targeting GARP: TGF-β1 complexes on Tregs for the immunotherapy of myeloproliferative neoplasms
CN117980324A (zh) 特异性结合ct45的抗原结合蛋白
JP2022518187A (ja) 抗体

Legal Events

Date Code Title Description
FZDE Discontinued